EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation
Open Access
- 31 August 2014
- journal article
- research article
- Published by Springer Nature in Nature Cell Biology
- Vol. 16 (10) , 972-981
Abstract
Hepatocellular carcinoma (HCC) is a frequent cancer with limited treatment options and poor prognosis. Tumorigenesis has been linked with macrophage-mediated chronic inflammation and diverse signalling pathways, including the epidermal growth factor receptor (EGFR) pathway. The precise role of EGFR in HCC is unknown, and EGFR inhibitors have shown disappointing clinical results. Here we discover that EGFR is expressed in liver macrophages in both human HCC and in a mouse HCC model. Mice lacking EGFR in macrophages show impaired hepatocarcinogenesis, whereas mice lacking EGFR in hepatocytes unexpectedly develop more HCC owing to increased hepatocyte damage and compensatory proliferation. Mechanistically, following interleukin-1 stimulation, EGFR is required in liver macrophages to transcriptionally induce interleukin-6, which triggers hepatocyte proliferation and HCC. Importantly, the presence of EGFR-positive liver macrophages in HCC patients is associated with poor survival. This study demonstrates a tumour-promoting mechanism for EGFR in non-tumour cells, which could lead to more effective precision medicine strategies.Keywords
This publication has 40 references indexed in Scilit:
- NF-κB and STAT3 – key players in liver inflammation and cancerCell Research, 2010
- Immunity, Inflammation, and CancerCell, 2010
- p38α MAPK inhibits JNK activation and collaborates with IκB kinase 2 to prevent endotoxin‐induced liver failureEMBO Reports, 2008
- Hepatocyte Necrosis Induced by Oxidative Stress and IL-1α Release Mediate Carcinogen-Induced Compensatory Proliferation and Liver TumorigenesisCancer Cell, 2008
- Contradictory functions of NF-κB in liver physiology and cancerCancer Letters, 2008
- The EGF receptor is required for efficient liver regenerationProceedings of the National Academy of Sciences, 2007
- p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathwayNature Genetics, 2007
- Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activationProceedings of the National Academy of Sciences, 2006
- Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis†Hepatology, 2005
- Inflammation and cancerNature, 2002